Eisai Co., Ltd. (TYO:4523)
4,370.00
+49.00 (1.13%)
Mar 27, 2025, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 216.14B JPY in the quarter ending December 31, 2024, with 21.63% growth. This brings the company's revenue in the last twelve months to 791.66B, up 5.63% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.
Revenue (ttm)
791.66B
Revenue Growth
+5.63%
P/S Ratio
1.57
Revenue / Employee
71.53M
Employees
11,067
Market Cap
1,231.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | 695.62B | 52.79B | 8.21% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,170.61B |
Daiichi Sankyo Company | 1,795.99B |
Takeda Pharmaceutical Company | 4,579.02B |
HOYA Corporation | 837.44B |
Otsuka Holdings | 2,329.86B |
Terumo | 1,011.15B |
Astellas Pharma | 1,867.63B |
Olympus | 993.33B |
Eisai News
- 24 days ago - LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight - Benzinga
- 4 weeks ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 4 weeks ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 6 weeks ago - Q3 2025 Eisai Co Ltd Earnings Presentation Transcript - GuruFocus
- 6 weeks ago - Eisai projects 42.5B yen global revenue for LEQEMBI in FY2024 amid pathway expansion - Seeking Alpha
- 6 weeks ago - Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Eisai GAAP EPS of ¥160.14, revenue of ¥601.16B; reaffirms FY outlook - Seeking Alpha
- 2 months ago - Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters